Key facts
- This page summarizes Marina Gofman Feler's Form 3 filing for Nano-X Imaging Ltd. (NNOX).
- 0 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 18 Mar 2026, 11:29.
Marina Gofman Feler - 18 Mar 2026 Form 3 Insider Report for Nano-X Imaging Ltd. (NNOX)
- Reporting relationship
- Chief Legal Officer
- Issuer ticker
- NNOX
- Reported as of
- 18 Mar 2026
- Net transaction value
- $0
- Reporting owner signature
- /s/ Marina Gofman Feler
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Marina Gofman Feler filed Form 3 for Nano-X Imaging Ltd. (NNOX) on 18 Mar 2026.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (1)
CIK 0002049106
Primary reporting owner
Gofman Feler Marina
- Relationship
- Chief Legal Officer
- Address
- C/O NANO-X IMAGING LTD., OFER TECH PARK, 94 SHLOMO SHMELTZER ROAD, PETACH TIKVA, ISRAEL
- Signature
- /s/ Marina Gofman Feler
- Signature date
- 18 Mar 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
NNOX
holding
Ordinary shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 20,000
- Date
- 18 Mar 2026
- Ownership
- Direct
NNOX
holding
Ordinary shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 26,316
- Date
- 18 Mar 2026
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
NNOX
holding
Derivative
Stock Option (right to buy ordinary shares)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Mar 2026
- Ownership
- Direct
- Underlying class
- Ordinary shares
- Underlying amount
- 15,000
- Exercise price
- $17.63
- Footnotes
- F2
NNOX
holding
Derivative
Stock Option (right to buy ordinary shares)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Mar 2026
- Ownership
- Direct
- Underlying class
- Ordinary shares
- Underlying amount
- 10,000
- Exercise price
- $17.63
- Footnotes
- F3
NNOX
holding
Derivative
Stock Option (right to buy ordinary shares)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Mar 2026
- Ownership
- Direct
- Underlying class
- Ordinary shares
- Underlying amount
- 30,000
- Exercise price
- $11.52
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
The ordinary shares reported in this row consist of shares underlying restricted share units that were granted to the Reporting Person on February 5, 2026 and of which 50% will vest on the 12-month anniversary of the grant date and the remaining 50% will vest upon the 24-month anniversary of the grant date.
Footnote F2
The options reported in this row were granted to the Reporting Person by the Issuer on November 7, 2022 and vest and become exercisable in 16 equal quarterly installments of 6.25% each on each three-month anniversary of the grant date, such that all options reported in this row will be exercisable on the four-year anniversary of that grant date (November 7, 2026).
Footnote F3
The options reported in this row were granted to the Reporting Person by the Issuer on April 28, 2023 and vest and become exercisable in 16 equal quarterly installments of 6.25% each on each three-month anniversary of the grant date, such that all options reported in this row will be exercisable on the four-year anniversary of that grant date (April 28, 2027).
Footnote F4
The options reported in this row were granted to the Reporting Person by the Issuer on May 23, 2023 and vest and become exercisable in 16 equal quarterly installments of 6.25% each on each three-month anniversary of the grant date, such that all options reported in this row will be exercisable on the four-year anniversary of that appointment date (May 23, 2027).